提醒：洁定集团首席执行官一小时后- 2025年与高层对话

currently have 27 companies joining our series and are in the process of registering more.As part of the series, we are hosting Q&A sessions with management teams and keyopinion leaders in the industry. Investors are welcome to submit questions in advance (feelfree to email) or participate in Q&A during the calls (current schedule below). Followingeach call, we will provide key takeaways as well as replays/transcripts.Please register via the above link, whereby you can sign up for your chosen company call.Current Schedule (UKT) Register here•28th February, 15:00 - Galapagos - Thad Huston, CFO & COO••7th March, 14:00 - Coloplast - Kristian Villumsen, CEO••24th March, 15:00 - Philips - Charlotte Hanneman, CFO••28th March, 15:00 - Recordati - Luigi La Corte, CFO••7th April, 15:00 - Genmab - Judith Klimovsky, Chief DevelopmentOfficer••23rd April, 14:00 - Elekta - Tobias Hägglöv, CFO••29th April, 14:00 - UCB - Emmanuel Caemayex, CCO••7th May, 15:00 - Novartis - Harry Kirsch, CFO••12th May, 15:00 - Lonza Group - Philippe Deecke, CFO••19th May, 14:00 - Vimian - Patrik Eriksson, CEO••21st May, 14:00 - GN Store Nord - Peter Karlstromer, CEO••23rd May, 13:30 - Demant - René Schneider, CFO••27th May, 15:00 - Getinge - Mattias Perjos, CEO••28th May, 15:00 - Spire Healthcare - Harbant Samra, CFO••4th June, 15:00 - ConvaTec - Karim Bitar, CEO••10th June, 15:00 - Roche - Matt Sause, CEO Roche Diagnostics••12th June, 14.15 - H Lundbeck - Charl Van Zyl, CEO and Joerg Hornstein, CFO *DATE•CHANGE*•18th June, 15:00 – Ambu – Britt Meelby Jensen, CEO••19th June, 16:00 - Sectra - Torbjörn Kronander, CEO••23rd June, 14:00 - Fresenius Medical Care - Helen Giza, CEO••27th June, 15:00 - Bayer - Stefan Oelrich, Head of the Pharmaceuticals Division••30th June, 15:00 - Straumann - Yang Xu, CFO• •1st July, 16:00 - GSK - Luke Miels, Chief CommercialOfficer*DATE CHANGE*••2nd July, 15:00 - Sonova - Arnd Kaldowski, CEO••22nd July, 14:00 - Fresenius SE - Michael Sen, CEO *DATE CHANGE*••23rd July, 15:00 - Carl Zeiss Meditec- Justus Wehmer, CFO *DATE CHANGE*••8th October, 15:00 - Oxford Nanopore - Gordon Sanghera, CEO, Nick Keher, CFO•Meet the AnalystsHassan Al-Wakeel, CFA, is a Director and Head of theEuropean Medical Technology & Services equity researchteam at Barclays. He ranked #1 in his sector in the 2024Institutional Investor / Extel survey. Hassan joinedBarclays in 2017; he has over a decade of experience inequity research, previously working as a Global MedTechanalyst at GLG Partners and starting his career at DeutscheBank. He is a CFA Charterholder and graduated with a FirstClass Master's degree in Engineering Science from OxfordUniversity with a focus on Biomedical Engineering.View Analyst PageJon Unwin is a Vice President and research analystcovering the European Medical Technologies & Servicessector. He joined Barclays in 2025, having previouslyworked at Bernstein covering Medtech and before thatcovering Capital Goods and Oil Services. He is currentlystudying for an MSc in Health Economics, Policy andManagement from LSE and is a Chartered Accountant. Jonbegan his career at EY in Assurance and has a Bachelor’sdegree in Maths with Mathematical Physics from UCL.View Analyst PageEmily Field is a Director and Head of the EuropeanPharmaceuticals team at Barclays. Ms. Field joinedBarclays and moved to London in December 2017, prior towhich she spent her career on the buy side in New YorkCity. Ms. Field worked at investment funds (including UBSO’Connor and Millennium Management) under variousstrategies, including Risk Arbitrage and Equity Long/Short.She has focused on fundamental analysis of thehealthcare/pharmaceutical sector for nearly 15 years. Shedouble majored in Economics and History at Yale Hassan Al-Wakeel, CFAJonathon Unwin+44 (0)20 7773 0354Barclays, UKRohit Rajan+91 (0) 22 6175 1698Barclays, UKCharles Pitman-King,CFA+44 (0)20 3134 6023Barclays, UKShirley Chen, PhDSidhartha Modi+91 (0)22 6175 1326Barclays, UKAnurag Surendra SharmaUniversity and is also a CFA Charterholder. Ms. Field isoriginally from Chicago, Illinois.View Analyst PageCharles Pitman-King joined Barclays in 2022 as a VP in theEuropean pharmaceutical team to cover a selection ofmid-cap companies. His previous experience includescovering both mid-cap European and large-cap USpharmaceutical companies since 2018, as well as broadsector themes, such as the rapidly evolving COVID-19pandemic and sector ESG themes. Prior to this, he has alsohad experience covering the Aerospace and Defencesector, and working in financial modelling. He holds a firstclass Masters in Mathematics from Durham University andhas been a CFA charterholder since 2019.View Analyst PageEuropean Medical Technology & ServicesEuropean Pharmaceuticals & Life Sciences +44 (0)20 7773 3898Barclays, UKMarco Pires-Cox+44 (0)20 3134 3421Barclays, UKEmily Field, CFA+44 (0)20 7773 6263Barclays, UK+44 (0)20 7773 2109Barclays, UK+91 (0)22 6175 4548Barclays, UK This event is intended for Barclays institutional